+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 45 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are studying BS01, a gene therapy delivered by intravitreal injection, in people aged 50 to 85 with geographic atrophy GA caused by dry age-related macular degeneration AMD. This Phase 12 multi-center trial aims to assess the safety and effectiveness of BS01. The study includes an initial dose-escalation phase followed by a dose-expansion phase to compare the selected dose against a sham injection control group. The trial has two parts Part 1 is an open-label dose-escalation study involving up to 10 patients to determine the best dose based on benefit and risk. Part 2 will involve up to 30 patients randomized to receive either the selected doses of BS01 or a sham injection without needle, allowing controlled comparison of safety and efficacy. BS01 is a recombinant adeno-associated virus vector expressing ChronosFP. Participants will undergo eye exams and imaging to monitor geographic atrophy area and visual acuity. The study will evaluate adverse events for safety over 12 months in Phase 1 and measure changes in best corrected visual acuity BCVA over 12 months in Phase 2. Assessments include fundus photography, fundus autofluorescence, and optical coherence tomography. Participants will be monitored for treatment side effects and disease progression throughout the study period.

Age: 50Years - 85YearsAll GendersPhase 1Phase 2
1 location
P

Actively Recruiting

Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.

Age: 60Years +All GendersPhase 2
78 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and lasting effects of a single intravitreal injection of 4D-150 compared to aflibercept in adults with diabetic macular edema DME. The study is a Phase 3, randomized, double-masked, active-controlled trial designed to assess visual acuity changes and disease severity over one year. Participants will be randomly assigned to receive either a single dose of 4D-150 or aflibercept eye injections. The 4D-150 treatment is given once on Day 1, while aflibercept is administered at appropriate visits. The study lasts for 52 weeks, focusing on visual outcomes and the need for additional aflibercept injections after the initial treatments. Throughout the study, participants will undergo regular eye examinations to monitor visual acuity using the Early Treatment Diabetic Retinopathy Study ETDRS scale and assessments of diabetic retinopathy severity. Researchers will also track the number of aflibercept injections needed after Week 4. Safety and durability of the treatments will be closely observed during the one-year follow-up period.

Age: 18Years +All GendersPhase 3
87 locations
P

Actively Recruiting

Researchers are evaluating JNJ-95804306, a drug being studied for safety, tolerability, and anti-tumor activity in adults with relapsed or refractory hematological malignancies, including acute myeloid leukemia AML, high-risk myelodysplastic syndromes MDS, chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL, and non-Hodgkin lymphoma NHL. The study is divided into two parts Part 1 focuses on dose escalation to find the recommended phase 2 dose RP2D, and Part 2 expands the dose to further assess safety and anti-tumor effects. The trial is sponsored by Janssen Research & Development, LLC and is a phase 1 interventional study. Participants in Part 1 receive JNJ-95804306 either alone or combined with standard of care SoC therapies depending on their specific cancer type and location. For AMLHR-MDS and CLLSLLNHL groups outside the US, treatments include JNJ-95804306 monotherapy or in addition to SoC therapies, administered orally or subcutaneouslyintravenously as appropriate. In US sites, only JNJ-95804306 monotherapy is given without SoC. Part 2 follows with participants receiving the determined RP2D regimens, maintaining the same treatment assignments as Part 1. Throughout the study, participants undergo regular monitoring for dose-limiting toxicities and adverse events for up to 6 years and 5 months. Researchers measure drug levels in the blood, treatment response rates such as complete and overall responses across different malignancies, and duration and time to response. Participants are also assessed for safety and tolerability continuously. The total study period extends up to 6 years and 5 months, with ongoing evaluation of treatment effects and participant health.

Age: 18Years +All GendersPhase 1
19 locations
C

Actively Recruiting

Researchers are evaluating treatments for non-small cell lung cancer NSCLC in adults with a specific KRAS G12D gene mutation. NSCLC is a common lung cancer type, and when it worsens after initial chemotherapy and immune therapy, options are limited. This study aims to compare a new drug, setidegrasib, with the standard drug docetaxel to see which better controls cancer progression and survival. Participants receive either setidegrasib or docetaxel through intravenous infusion. Setidegrasib is given on days 1, 8, and 15 of each 21-day cycle, while docetaxel is given on day 1 of each cycle. Treatment continues until cancer worsens, side effects prevent further use, or other medical decisions stop treatment. Some on docetaxel may switch to setidegrasib if their cancer progresses. Tumor scans are done every 6 weeks in the first year and every 9 weeks afterwards. During the study, participants have regular safety checks and monitoring of their health. Researchers assess how long cancer stays controlled without worsening and overall survival. They also measure symptoms, tumor response, drug processing in the body, and side effects. After progression, follow-up calls occur every 12 weeks to check on the participants condition. The study may last up to about four years depending on the outcome measures.

Age: 18Years +All GendersPhase 3
23 locations
O

Actively Recruiting

Researchers are evaluating the effects of cannabidiol oral solution CBD-OS on focal-onset seizures in participants aged 12 to 75 years. This phase 1b open-label study aims to assess how CBD-OS reduces seizure frequency and impacts health outcomes in both early line and treatment-resistant focal seizure patients. The study also investigates safety, pharmacokinetics, and factors influencing treatment response through brain imaging and neuropsychological tests in a substudy. Participants will receive open-label CBD-OS according to the approved local dosing guidelines. The study monitors participants who are on stable antiseizure medication regimens, and treatment response will be compared to baseline seizure frequency. This trial is designed as a single-group study without placebo or comparator arms. During the study, participants will have their focal seizure counts tracked and compared to baseline over a period of up to 16 weeks. Evaluations include safety assessments, pharmacokinetic sampling, functional MRI, and neuropsychological testing for a subset of participants. The total study duration spans from screening through treatment and monitoring until study completion, with ongoing safety and efficacy evaluations.

Age: 12Years - 75YearsAll GendersPhase 1
24 locations
S

Actively Recruiting

Researchers are evaluating the use of apixaban compared to aspirin to prevent stroke or death in patients who have had a recent intracerebral hemorrhage ICH and also have atrial fibrillation AF. This phase III randomized, double-blinded trial aims to determine if apixaban is superior in preventing any type of stroke or death, as well as if it leads to better functional recovery measured by the modified Rankin Scale. The study will enroll 700 patients and follow them for 12 to 36 months to assess these outcomes. Participants will be randomly assigned to receive either apixaban or aspirin. Apixaban dosing is typically 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for those meeting specific criteria such as older age, lower body weight, or certain medication use. Aspirin is given once daily at a dose of 81 mg. The study includes a treatment period after recent ICH, with careful monitoring for safety and efficacy. During the study, participants will undergo regular assessments including evaluation of stroke occurrence, death, and changes in functional status using the modified Rankin Scale. Safety and adherence will be monitored throughout the follow-up period, which ranges from 12 months up to 3 years. The research team will collect data to understand the benefits and risks of apixaban versus aspirin in this patient population.

Age: 18Years +All GendersPhase 3
187 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of Cardiac Contractility Modulation CCM therapy in patients with heart failure who have a left ventricular ejection fraction LVEF between 40% and 70%. The study is a randomized, quadruple-blind, sham-controlled trial conducted at multiple centers across the US and internationally. It includes two parts with distinct scientific goals the first part focuses on functional capacity and health status, while the second part focuses on clinical outcomes. Participants will have the OPTIMIZER Smart Mini System implanted. They will be randomly assigned in a 21 ratio to either receive active CCM therapy CCM ON or a sham treatment with the device turned off CCM OFF during the first 18 months. CCM therapy involves seven one-hour treatment phases spaced evenly over 24 hours daily. After the 18-month blinded phase, those in the sham group will have CCM therapy turned on for the remainder of the study. The trial will enroll about 1500 subjects in total and follow them for up to 18 months or longer through both parts. Participants will undergo screening and baseline tests before implantation. Researchers will monitor their functional capacity using the 6-minute walk test and assess health status with the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety will be tracked by recording device- or procedure-related complications within the first year. Clinical outcomes including mortality and morbidity will be evaluated over 18 months. Follow-up visits and data collection will continue through the study duration to assess these measures and the long-term safety and effectiveness of CCM therapy.

Age: 18Years +All GendersPhase Not Applicable
67 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of a cardiac rehabilitation program for adults who have had a stroke. The study aims to see if adding cardiac rehabilitation to the usual care improves recovery of function and reduces hospital readmission, recurrent stroke, and mortality rates. This research targets adults diagnosed with ischemic or hemorrhagic stroke who have been medically cleared for cardiac rehabilitation. Participants in the study are randomly assigned to one of two groups. One group receives a traditional medically supervised cardiac rehabilitation program consisting of 36 sessions of progressive exercise lasting 30 to 50 minutes each, combined with educational sessions on cardiovascular risk factors such as diet, smoking cessation, physical activity, medication management, and behavior change. The other group receives standard care therapies, including physical, occupational, and speech therapy as prescribed by their physicians. The rehabilitation program includes close monitoring with telemetry and support from cardiac rehabilitation nurses and exercise physiologists. During the study, participants will undergo assessments including walking tests, cognitive and quality of life evaluations, and monitoring of hospital readmission and stroke recurrence up to one year after stroke. Researchers will measure changes from baseline at 30 days post-stroke to 120 days post-stroke, as well as outcomes at one year. These assessments help evaluate participants physical function, cognitive status, and overall stroke recovery. The total study participation spans from initial assessment through follow-up evaluations over the course of one year post-stroke.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

This trial investigates whether middle meningeal artery embolization MMAE can be a safe and effective alternative to conventional open surgery for patients with moderately symptomatic chronic subdural hematoma CSDH. The study aims to determine if MMAE reduces the need for additional rescue surgery or deaths compared to standard surgery and to assess the safety of both treatments in this patient group. Participants will be randomly assigned to receive either MMAE, which involves particle embolization of the middle meningeal artery using specialized devices, or conventional surgery through burr holes or craniotomy to drain the hematoma. Treatments are delivered soon after randomization, and participants in both groups are monitored closely for outcomes. During the study, participants will share medical history, undergo physical exams, blood tests, and head CT scans. They will also complete questionnaires and report any adverse events. Researchers will follow participants for about 180 to 210 days after treatment to measure the need for rescue surgery or death and evaluate treatment safety. This process includes regular evaluations to track progress and health status.

Age: 40Years - 90YearsAll GendersPhase Not Applicable
31 locations

1-10 of 45

1